MicroRNA‑135a expression is upregulated in hepatocellular carcinoma and targets long non‑coding RNA TONSL‑AS1 to suppress cell proliferation

Deng,Xuesong; Cheng,Jun; Zhan,Naiyang; Chen,Jianwei; Zhan,Yongqiang; Ni,Yong; Liao,Caixian

doi:10.3892/ol.2021.13069

MicroRNA‑135a expression is upregulated in hepatocellular carcinoma and targets long non‑coding RNA TONSL‑AS1 to suppress cell proliferation

Authors:
- Xuesong Deng
- Jun Cheng
- Naiyang Zhan
- Jianwei Chen
- Yongqiang Zhan
- Yong Ni
- Caixian Liao
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Shenzhen University, Health Science Center/Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, PR. China
Published online on: September 24, 2021 https://doi.org/10.3892/ol.2021.13069
Article Number: 808
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of long non‑coding RNAs (lncRNAs) results in development of human diseases, including hepatocellular carcinoma (HCC). lncRNA TONSL‑AS1 has been reported to act as a tumor suppressor in gastric cancer. The present study aimed to investigate the role of TONSL‑AS1 in hepatocellular carcinoma (HCC). Reverse transcription‑quantitative PCR analysis was performed to detect the expression levels of TONSL‑AS1 and microRNA (miRNA/miR)‑135a in HCC tissues and paired adjacent normal tissues. A 5‑year follow‑up study was performed to determine the prognostic value of TONSL‑AS1 in HCC. The association between miR‑135a and TONSL‑AS1 was assessed via overexpression experiments. The Cell Counting Kit‑8 assay was performed to assess cell proliferation. The results demonstrated that TONSL‑AS1 expression was downregulated in HCC tissues, which was associated with a lower survival rate in patients with HCC. TONSL‑AS1 and miR‑135a were predicted to interact with each other, whereby overexpression of miR‑135a downregulated TONSL‑AS1 expression. The results demonstrated that TONSL‑AS1 and miR‑135a were inversely correlated with each other. Notably, overexpression of TONSL‑AS1 inhibited HCC cell proliferation, while overexpression of miR‑135a promoted HCC cell proliferation and decreased the effect of overexpression of TONSL‑AS1 on cell proliferation. Taken together, the results of the present study suggest that miR‑135a expression is upregulated in HCC and targets lncRNA TONSL‑AS1 to suppress cell proliferation.

View Figures

View References

1	Zuo TT, Zheng RS, Zhang SW, Zeng HM and Chen WQ: Incidence and mortality of liver cancer in China in 2011. Chin J Cancer. 34:508–513. 2015. View Article : Google Scholar : PubMed/NCBI
2	Altekruse SF, Henley SJ, Cucinelli JE and McGlynn KA: Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Kulik L and El-Serag HB: Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
5	Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q and Yee HT: Hepatitis B vs hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 12:642012. View Article : Google Scholar : PubMed/NCBI
6	Lu T, Seto WK, Zhu RX, Lai CL and Yuen MF: Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol. 19:8887–8894. 2013. View Article : Google Scholar : PubMed/NCBI
7	Saran U, Humar B, Kolly P and Dufour JF: Hepatocellular carcinoma and lifestyles. J Hepatol. 64:203–214. 2016. View Article : Google Scholar : PubMed/NCBI
8	Tarocchi M, Polvani S, Marroncini G and Galli A: Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 20:11630–11640. 2014. View Article : Google Scholar : PubMed/NCBI
9	Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, et al: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011. View Article : Google Scholar : PubMed/NCBI
10	Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al: Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 19:347–358. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen S, Wang C, Xue Y, Huang F, Fang Q, et al: lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. Mol Oncol. 13:2246–2258. 2019. View Article : Google Scholar : PubMed/NCBI
12	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li CH and Chen Y: Targeting long non-coding RNAs in cancers: Progress and prospects. Int J Biochem Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang P, Yang X, Zhao L, Liu D, Liu J and Ding Y: A novel long non-coding RNA TONSL-AS1 regulates progression of gastric cancer via activating TONSL. Exp Cell Res. 382:1114532019. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, Luo X, Zheng F, Liu R, Zhang H and Ma D: miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 12:1112012. View Article : Google Scholar : PubMed/NCBI
16	Park S, Choi S, Cho YA, Sinn DH, Kim JM, Park CK and Ha SY: Evaluation of the American joint committee on cancer (AJCC) 8th edition staging system for hepatocellular carcinoma in 1,008 patients with curative resection. Cancer Res Treat. 52:1145–1152. 2020.PubMed/NCBI
17	Lang N, Wang C, Zhao J, Shi F, Wu T and Cao H: Long non-coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR-149/PKM2 axis in non-small-cell lung cancer. Mol Med Rep. 21:1509–1516. 2020.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
20	Mao XP, Zhang LS, Huang B, Zhou SY, Liao J, Chen LW, Qiu SP and Chen JX: Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med. 13:862015. View Article : Google Scholar : PubMed/NCBI
21	Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J, et al: MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 56:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zeng YB, Liang XH, Zhang GX, Jiang N, Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI
23	Xie Y, Li F, Li Z and Shi Z: miR-135a suppresses migration of gastric cancer cells by targeting TRAF5-mediated NF-κB activation. Onco Targets Ther. 12:975–984. 2019. View Article : Google Scholar : PubMed/NCBI
24	Yang C, Zheng X, Ye K, Sun Y, Lu Y, Fan Q and Ge H: miR-135a inhibits the invasion and migration of esophageal cancer stem cells through the hedgehog signaling pathway by targeting Smo. Mol Ther Nucleic Acids. 19:841–852. 2020. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Yang J, Zhang H, Liao Y, Xu D and Ma S: Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells. Oncol Lett. 20:914–920. 2020. View Article : Google Scholar : PubMed/NCBI